Systemic hormone therapy is different from vaginal hormone therapy + we recommend speaking with providers that follow the North American Menopause Society Guidelines to help people manage their genitourinary symptoms
Hyperprolactinemia is associated with insulin resistance which improves with dopamine agonist therapy which might be related to the therapy associated weight loss and an activation of insulin signaling (5962)
Role of microbiota-gut-brain axis in regulating dopaminergic signaling
However, individual timelines vary significantly based on starting dose, escalation speed, and genetic factors
Certain MNTI cells may also express Ki-67/CD99 positivity, which indicates a faster growth rate (11)
Rudzinska A, Piotrowicz K, Perera I, Gryglewska B, Gasowski J